Monday, 31 August 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

BIOTALYS Stock Bullish Momentum With A 22.7% Jump Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with BIOTALYS (BTLS.BR) rising 22.7% to €3.73 on Friday, after two sequential sessions in a row of gains. BEL 20 jumped 1.41% to €3,578.91, after two consecutive sessions in a row of gains, on what was an all-around up trend exchanging session today.

About BIOTALYS

Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOTALYS's stock is considered to be oversold (<=20).

More news about BIOTALYS (BTLS.BR).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStockBIOTALYSBTLS.BR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com